Antimicrobial susceptibility patterns and distribution of BlaAXA genes among Acinetobacter spp. isolated from patients at Tehran hospitals

Japanese Journal of Infectious Diseases

Volumn 61, Issue 4, 2008, Pages 274-278

  Feizabadi, M M ^a   Fathollahzadeh, B ^a   Taherikalani, M ^c   Rasoolinejad, M ^b   Sadeghifard, N ^c   Aligholi, M ^a   Soroush, S ^a   Mohammadi Yegane, S ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN BLAOXA; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; AGAR DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; ENZYME LOCALIZATION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; QUANTITATIVE ANALYSIS; RELIABILITY; SPECIES DIFFERENTIATION; SPECIES IDENTIFICATION;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALIZATION; HUMANS; IRAN; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

EID: 48749098836     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bergogne, B.-E. and Towner, K.-J. (1996): Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin. Microbiol. Rev., 9, 148-165.
2. Towner, K.-J. (2001): Acinetobacter in intensive care units. CPD Infect., 3, 99-102.
3. Livermore, D.-M. (2003): The threat from the pink corner. Ann. Med., 35, 226-234.
4. Gaynes, R., Edwards, J.R. and the National Nosocomial Infections Surveillance System (2005): Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis., 41, 848-854.
5. Livermore, D.-M. (2002): The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investig. Drugs, 3, 218-224.
6. Brown, S. and Amyes, S. (2006): OXA-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother, 57, 1-3.
7. Heritier, C., Poirel, L., Fournier, P.-E., et al. (2005): Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob. Agents Chemother., 49, 4174-4179.
8. National Committee for Clinical Laboratory Standards (2003): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, p. 1. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Raffaele, Z., Margherita, C., Maria, B., et al. (2004): Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J. Clin. Microbiol., 42, 946-953.
10. Brown, S., Young, H.-K. and Amyes, S.-G. (2005): Characterization of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect., 11, 15-23.
11. Neil., W., Matthew, J.E., Juliana, M.C., et al. (2006): Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents, 27, 351-356.
12. Buisson, Y., Van Nhieu, G.-T., Ginot, L., et al. (1990): Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage. J. Hosp. Infect., 15, 83-93.
13. Maria, C.-B., Soraya, S.-A., Suzane, S., et al. (2004): Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int. J. Infect. Dis., 8, 284-291.
14. Vincent, J.-L., Bihari, D.-J., Suter, P.-M., et al. (1995): The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory. JAMA, 274, 639-644.
15. Kollef, M.-H. and Fraser, V.-J. (2001): Antibiotic resistance in the intensive care unit. Ann. Intern. Med., 134, 298-314.
16. Ruiz, J., Nunez, M.-L., Perez, J., et al. (1999): Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur. J. Clin. Microbiol. Infect. Dis., 18, 292-295.
17. AfzalSha, M. and Livermore, D.-M. (1998): Worldwide emergence of carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother., 41, 576-577.
18. Da Silva, G.-J., Leitao, G.-J. and Peixe, L. (1999): Emergence of carbapenem- hydrolyzing enzymes in Acinetobacter baumannii clinical isolates. J. Clin. Microbiol., 37, 2109-2110.
19. Bou, G.-G., Cervero, M.-A. and Dominguez, C.-Q. (2000): Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J. Clin. Microbiol., 38, 3299-3330.
20. Dalla-Costa, L.-M., Coelho, J.-M., Souza, H.-A., et al. (2003): Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol., 41, 3403-3406.
21. Da Silva, G.-J., Quinteira, S., Bertolo, E., et al. (2004): Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J. Antimicrob. Chemother., 54, 255-258.
22. Heritier, C., Dubouix, A., Poirel, L., et al. (2005): A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J. Antimicrob. Chemother., 55, 115-118.
23. Jeon, B.-C., Jeong, S.-H., Bae, I.-K., et al. (2005): Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J. Clin. Microbiol., 43, 2241-2245.
24. Lopez-Otsoa, F.-L., Gallego, K.-J., Towner, L., et al. (2002): Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates Erom a hospital in northern Spain. J. Clin. Microbiol., 40, 4741-4743.
25. Marque, S., Poirel, L., Heritier, C., et al. (2005): Regional occurrence of plasmid mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J. Clin. Microbiol., 43, 4885-4888.
26. Naas, T., Levy, M., Hirschauer, C., et al. (2005): Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J. Clin. Microbiol., 43, 4826-4829.
27. like carbapenemase gene intrinsic to this species. J. Clin. Microbiol., 44, 2974-2976.
28. Turton, J.F., Ward, M.E., Woodford, N., et al. (2006): The role of IS Aba1 on expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258, 72-77.
29. Jan, W.-R. and Niels, H. (2006): OXA-carbapenemase. J. Antimicrobiol. Chemothr., 57, 373-383.